How to buy ADC Therapeutics stock (ADCT)

ADC Therapeutics is a biotechnology business based in the US. ADC Therapeutics shares (ADCT) are listed on the NYSE and all prices are listed in US Dollars. Its last market close was $1.96 – an increase of 3.7% over the previous week. ADC Therapeutics employs 273 staff and has a trailing 12-month revenue of around $70.7 million.

Our top picks for where to buy ADC Therapeutics stock

Buy ADC Therapeutics stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

ADC Therapeutics stock price (NYSE: ADCT)

Use our graph to track the performance of ADCT stocks over time.

ADC Therapeutics shares at a glance

• Key figures

Information last updated 2024-12-18.

Latest market close	$1.96
52-week range	$1.28 - $6.04
50-day moving average more info button	$2.67
200-day moving average more info button	$3.41
Wall St. target price	$8.40
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-2.39

Is it a good time to buy ADC Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

ADC Therapeutics price performance over time

Historical closes compared with the close of $1.96 from 2024-12-20

1 week (2024-12-13)	3.70%
1 month (2024-11-22)	-1.51%
3 months (2024-09-20)	-41.14%
6 months (2024-06-21)	-26.04%

1 year (2023-12-22)	32.43%
2 years (2022-12-22)	-36.36%
3 years (2021-12-21)	20.35
5 years (2019-12-18)	N/A

ADC Therapeutics financials

Revenue TTM	$70.7 million
Gross profit TTM	$35.1 million
Return on assets TTM	-21.17%
Return on equity TTM	-705.53%
Profit margin	-300%
Book value	$-1.78
Market Capitalization more info button	$184.7 million

TTM: trailing 12 months

ADC Therapeutics share dividends

We're not expecting ADC Therapeutics to pay a dividend over the next 12 months.

ADC Therapeutics share price volatility

Over the last 12 months, ADC Therapeutics's shares have ranged in value from as little as $1.28 up to $6.04. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while ADC Therapeutics's is 1.602. This would suggest that ADC Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

ADC Therapeutics overview

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U. S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets.

Frequently asked questions

null
What percentage of ADC Therapeutics is owned by insiders or institutions?
Currently 20.642% of ADC Therapeutics shares are held by insiders and 63.225% by institutions. How many people work for ADC Therapeutics?
Latest data suggests 273 work at ADC Therapeutics. When does the fiscal year end for ADC Therapeutics?
ADC Therapeutics's fiscal year ends in December. Where is ADC Therapeutics based?
ADC Therapeutics's address is: BiopOle, Epalinges, Switzerland, 1066 What is ADC Therapeutics's ISIN number?
ADC Therapeutics's international securities identification number is: CH0499880968